The Food and Drug Administration, under heavy criticism over its decision last month to approve Biogen’s Alzheimer’s drug Aduhelm, has revised the medicine’s prescribing information in an effort to focus treatment on the type of patients included in clinical testing. The FDA’s June 7 approval of Aduhelm was made more controversial by the agency’s decision… Read More »
The PI3K inhibitors were once viewed as a blockbuster opportunity in blood cancer. But patient deaths in clinical trials for earlier-line use of Gilead Sciences’ first-to-market Zydelig dashed that hope. Now, in what could be viewed as a redemption of the drug class, Bayer’s Aliqopa has come up with a success safely. Adding Aliqopa to… Read More »
Metformin, a drug used in the treatment of type 2 diabetes, may have a role in reversing weight gain in people with HIV on antiretroviral treatment, a small preliminary study suggests. The drug’s impact on weight gain in people with HIV needs to be tested in larger studies, especially in women with HIV of African… Read More »
This 60-second advertisement for Trulicity, a medication for diabetes, is one of the most feel-good medication commercials I’ve ever seen. The narrator never uses the scare tactic of so many other ads, listing the terrible things that could happen if you don’t take the treatment. Instead, from start to finish, music, images, and spoken words… Read More »
A long-haired male golden hamster (via Wikipedia & Creative Commons) Earlier this week, a powerful opinion piece, “It Has Come To This: Ignore the CDC,” co-authored by former National Institutes of Health director Harold Varmus, was published in the New York Times. That’s on the science side. On the PR and journalism side, it has… Read More »
Drug pricing rhetoric has been quieted amid the COVID-19 pandemic and protests over racial justice, but President Donald Trump revived the topic on Friday. With four executive orders, the president pledged to lower prices through several previous policy proposals with months to go until the election. While Trump’s executive orders ran into immediate pushback from the drug industry, they won’t affect pricing all… Read More »
Print this page PRINCETON, N.J.–(BUSINESS WIRE)–May 15, 2020 — Bristol Myers Squibb (NYSE: BMY) today announced that Pomalyst ® (pomalidomide) was approved by the U.S. Food and Drug Administration (FDA) for patients with AIDS-related Kaposi sarcoma whose disease has become resistant to highly active antiretroviral therapy (HAART), or in patients with Kaposi sarcoma who are… Read More »